< Back
Sign In to Follow Application
View All Documents & Correspondence
Login

"Pharmaceutical Composition Comprising Transiently Surviving Ctl"

Abstract: Disclosed are transplantation cells for an immunotherapy, which are applicable to a wider variety of patients compared to conventional transplantation cells for immunotherapies, and which can survive transiently so that severe GVH disease cannot be induced. Specifically disclosed is a pharmaceutical composition containing cells derived from human hematopoietic stem cells. In the pharmaceutical composition, the genetic locus of at least one human HLA class I molecule in the cells contains at least one antigen for which the type of matching of the cell is identical to that of a patient. The genetic locus of each of the human HLA class I and II molecules in the cells contains at least one antigen for which the type of matching of the cell is not identical to that of a patient, and the cells derived from the hematopoietic stem cells do not cause acute GVH disease having a severity of level III or IV in the body of a patient even when the cells survive in the patient permanently.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
05 March 2012
Publication Number
35/2012
Publication Type
INA
Invention Field
PHARMACEUTICALS
Status
Email
Parent Application

Applicants

THE UNIVERSITY OF TOKYO
3-1, HONGO 7-CHOME, BUNKYO-KU, TOKYO 1138654, JAPAN

Inventors

1. YAMASHITA, NAOHIDE
C/O THE UNIVERSITY OF TOKYO, 3-1, HONGO 7-CHOME, BUNKYO-KU, TOKYO 1138654, JAPAN
2. NAGAYAMA, HITOMI
C/O THE UNIVERSITY OF TOKYO, 3-1, HONGO 7-CHOME, BUNKYO-KU, TOKYO 1138654, JAPAN
3. FUJITA, SHIGEHARU
C/O THE UNIVERSITY OF TOKYO, 3-1, HONGO 7-CHOME, BUNKYO-KU, TOKYO 1138654, JAPAN

Specification

Disclosed are transplantation cells for an immunotherapy, which are applicable to a wider variety of patients compared to conventional transplantation cells for immunotherapies, and which can survive transiently so that severe GVH disease cannot be induced. Specifically disclosed is a pharmaceutical composition containing cells derived from human hematopoietic stem cells. In the pharmaceutical composition, the genetic locus of at least one human HLA class I molecule in the cells contains at least one antigen for which the type of matching of the cell is identical to that of a patient. The genetic locus of each of the human HLA class I and II molecules in the cells contains at least one antigen for which the type of matching of the cell is not identical to that of a patient, and the cells derived from the hematopoietic stem cells do not cause acute GVH disease having a severity of level III or IV in the body of a patient even when the cells survive in the patient permanently.

Documents

Application Documents

# Name Date
1 546-MUMNP-2012-AbandonedLetter.pdf 2018-10-31
1 546-MUMNP-2012-FORM-13--(05-03-2012).pdf 2012-03-05
2 546-MUMNP-2012-ABSTRACT.pdf 2018-08-11
2 546-MUMNP-2012-CLAIMS (MARKED COPY)-05-03-2012.pdf 2012-03-05
3 546-MUMNP-2012-CLAIMS.pdf 2018-08-11
3 546-MUMNP-2012-AFR-31-05-2012.pdf 2012-05-31
4 ABSTRACT1.jpg 2018-08-11
4 546-MUMNP-2012-CORRESPONDENCE(19-7-2013).pdf 2018-08-11
5 546-MUMNP-2012-SEQUENCE LISTING.pdf 2018-08-11
5 546-MUMNP-2012-CORRESPONDENCE(27-3-2012).pdf 2018-08-11
6 546-MUMNP-2012-POWER OF ATTORNEY(27-3-2012).pdf 2018-08-11
6 546-MUMNP-2012-CORRESPONDENCE(4-9-2012).pdf 2018-08-11
7 546-MUMNP-2012-OTHER PCT DOCUMENT.pdf 2018-08-11
7 546-MUMNP-2012-CORRESPONDENCE.pdf 2018-08-11
8 546-MUMNP-2012-OTHER DOCUMENT.pdf 2018-08-11
8 546-MUMNP-2012-DESCRIPTION(COMPLETE).pdf 2018-08-11
9 546-MUMNP-2012-DRAWING.pdf 2018-08-11
9 546-MUMNP-2012-FORM PCT-ISA-210.pdf 2018-08-11
10 546-MUMNP-2012-FER.pdf 2018-08-11
10 546-MUMNP-2012-FORM PCT-IB-304.pdf 2018-08-11
11 546-MUMNP-2012-FORM 1.pdf 2018-08-11
11 546-MUMNP-2012-FORM 5.pdf 2018-08-11
12 546-MUMNP-2012-FORM 18(19-7-2013).pdf 2018-08-11
12 546-MUMNP-2012-FORM 3.pdf 2018-08-11
13 546-MUMNP-2012-FORM 2(TITLE PAGE).pdf 2018-08-11
13 546-MUMNP-2012-FORM 3(4-9-2012).pdf 2018-08-11
14 546-MUMNP-2012-FORM 2.pdf 2018-08-11
15 546-MUMNP-2012-FORM 2(TITLE PAGE).pdf 2018-08-11
15 546-MUMNP-2012-FORM 3(4-9-2012).pdf 2018-08-11
16 546-MUMNP-2012-FORM 18(19-7-2013).pdf 2018-08-11
16 546-MUMNP-2012-FORM 3.pdf 2018-08-11
17 546-MUMNP-2012-FORM 5.pdf 2018-08-11
17 546-MUMNP-2012-FORM 1.pdf 2018-08-11
18 546-MUMNP-2012-FORM PCT-IB-304.pdf 2018-08-11
18 546-MUMNP-2012-FER.pdf 2018-08-11
19 546-MUMNP-2012-DRAWING.pdf 2018-08-11
19 546-MUMNP-2012-FORM PCT-ISA-210.pdf 2018-08-11
20 546-MUMNP-2012-DESCRIPTION(COMPLETE).pdf 2018-08-11
20 546-MUMNP-2012-OTHER DOCUMENT.pdf 2018-08-11
21 546-MUMNP-2012-CORRESPONDENCE.pdf 2018-08-11
21 546-MUMNP-2012-OTHER PCT DOCUMENT.pdf 2018-08-11
22 546-MUMNP-2012-CORRESPONDENCE(4-9-2012).pdf 2018-08-11
22 546-MUMNP-2012-POWER OF ATTORNEY(27-3-2012).pdf 2018-08-11
23 546-MUMNP-2012-CORRESPONDENCE(27-3-2012).pdf 2018-08-11
23 546-MUMNP-2012-SEQUENCE LISTING.pdf 2018-08-11
24 546-MUMNP-2012-CORRESPONDENCE(19-7-2013).pdf 2018-08-11
24 ABSTRACT1.jpg 2018-08-11
25 546-MUMNP-2012-CLAIMS.pdf 2018-08-11
25 546-MUMNP-2012-AFR-31-05-2012.pdf 2012-05-31
26 546-MUMNP-2012-ABSTRACT.pdf 2018-08-11
27 546-MUMNP-2012-AbandonedLetter.pdf 2018-10-31

Search Strategy

1 patseer_22-11-2017.pdf